阿德福韦酯与扶正化淤胶囊联合治疗慢性乙型肝炎的疗效观察  

Therapeutic effects observation of adefovior dipivoxil（ADV） and Fu Zheng Hua Yu capsule treatment for chronic hepatitis B patients

作　　者：潘晓华 李仲平 

机构地区：[1]上海市南汇区南华医院肝炎科,上海201300

出　　处：《世界感染杂志》2008年第3期207-209,共3页World Journal of Infection

摘　　要：目的观察阿德福韦酯与扶正化淤胶囊联合治疗慢性乙型肝炎的疗效。方法85例病人随机分为阿德福韦酯组和阿德福韦酯与扶正化淤胶囊联合组，检测肝功能、乙型肝炎血清学标志物（HBVM）、HBVDNA和肝纤维化指标（血清HA、LN、PCⅢ、Ⅳ—C）等。结果6mo后两组肝功能恢复较明显，但ALT、AST的复常率与好转率比较无显著差异（P〉0．05）；两组HBeAg阴转率、HBeAg／HBeAb血清转换率与HBVDNA阴转率比较均无显著差异（P〉0．05）；联合组肝纤维化恢复更明显，与阿德福韦酯组比较有显著差异，肝纤维化指标（血清HA、LN、PCⅢ、Ⅳ—C）两组比较P〈0.01。结论阿德福韦酯与扶正化淤胶囊联合治疗抗肝纤维化有一定的意义。Objective To evaluate the efficacy adefovior dipivoxil（ADV） and Fu Zheng Hua Yu capsule treatment for chronic hepatitis B patients. Methods Eighty-five patients were randomly put into two groups： ADV group, ADV and Fu Zheng Hua Yu capsule united group. Observe liver functions （ALT, AST）, HBVM, HBV-DNA and HA, LN, PCⅢ, Ⅳ-C. Results The rations of recovery for liver functions and the negativity rate of HBeAg, HBV-DNA including sero-conversion rate of HBeAg/HbeAb were increased after treatment. While the difference between the two groups were not satistically significant （P〉0.05）. The serum levels of HA, LN, PCⅢ, Ⅳ-C were better before treatment. There were significant difference in the united group and ADV group with the serums of signs of the hepatic fibrosis（HA, LN, PCⅢ, Ⅳ-C）. Conclusions This indicat6d the ADV and Fu Zheng Hua Yu capsule has some efficacy of Anti-hepatic fibrosis.

关 键 词：阿德福韦酯 扶正化淤胶囊 慢性乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]